EP Patent

EP1791544A4 — DERIVATIVES OF QUINAZOLIN AS METABOLICALLY INERT ANTIFOLIC

Assigned to Lundbeck NA Ltd · Expires 2007-09-12 · 19y expired

What this patent protects

The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.

USPTO Abstract

The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.

Drugs covered by this patent

Patent Metadata

Patent number
EP1791544A4
Jurisdiction
EP
Classification
—
Expires
2007-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Lundbeck NA Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.